查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018931

人用狂犬疫苗市场：2026-2032年全球市场预测（依疫苗类型、疫苗分类、给药途径、製剂、通路及最终用户划分）

Human Rabies Vaccines Market by Vaccine Type, Vaccine Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年人类狂犬病疫苗市场价值11亿美元，预计2026年将成长至11.5亿美元，复合年增长率为4.76%，到2032年将达到15.2亿美元。

主要市场统计数据
基准年 2025 11亿美元
预计年份：2026年 11.5亿美元
预测年份：2032年 15.2亿美元
复合年增长率 (%) 4.76%

人类狂犬病疫苗的策略部署：重点关注临床紧迫性、近期技术进步以及影响相关人员决策的政策重点。

人类用狂犬病疫苗仍然是全球公共卫生对抗狂犬病工作的基石，一旦出现临床症状，狂犬病几乎必然致命。免疫学、生产平台和接种技术的进步提高了疫苗的安全性和物流可行性，但疫苗取得、公众意识和低温运输基础设施方面的持续差异导致不同地区疫苗保护程度参差不齐。临床需求显而易见：透过接种疫苗和及时进行暴露后预防是预防死亡和控制感染传播的最有效手段。

科学创新、供应链优化和跨部门伙伴关係如何改变全球人类狂犬病疫苗接种的格局和专案优先事项？

人类狂犬病疫苗领域正经历一场变革，其驱动力来自科学创新、方案优化以及不断发展的供应链生态系统。新型生产技术和细胞基材技术的进步降低了疫苗的反应原性，并稳定了抗原品质。加之法规结构的强化，多个地区的核准流程正在加速推进。同时，皮内注射和减量接种方案的引入，透过提高成本效益和扩大现有疫苗覆盖人群，正在重塑免疫接种方案。

评估 2025 年美国关税变化对人类狂犬病疫苗供应链、筹资策略和本地化决策的影响。

美国近期就2025年即将生效的关税谈判和贸易政策调整，为狂犬病疫苗的生产、采购和分销带来了新的考量。关税可能影响进口原料、生技药品和成品疫苗的下游成本，进而影响公共卫生机构和私人经销商的筹资策略。如果关税导致投入成本上升，製造商可能需要调整筹资策略，推进关键生产环节的本地化，或与供应商重新谈判合约条款，以确保利润率和维持供应稳定性。

针对每种疫苗类型、分类、给药途径、配方、最终用户和分销管道，制定临床引进和商业策略的细分市场洞察。

细分市场分析揭示了每种疫苗类型、分类、给药途径、製剂、最终用户和分销管道的不同需求驱动因素、临床考虑和商业性管道。依疫苗类型分析显示，暴露后预防和暴露前预防在操作上有明显差异。暴露后预防计画优先考虑快速取得、紧急物流以及与创伤护理和免疫球蛋白疗法的整合，而暴露前预防计画则着重于针对高风险族群的定向宣传活动和职业免疫接种计画。疫苗分类揭示了源自人类二倍体细胞、纯化鸡胚细胞和纯化Vero细胞的疫苗之间的差异，这些差异会影响区域耐受性、生产规模化和监管熟悉程度，进而影响疫苗的普及曲线和采购偏好。

流行病学、法规结构和供给能力的区域差异决定了重点地区疫苗部署策略的差异化。

区域趋势导致疾病负担、监管管道和供应系统能力有显着差异，这些差异决定了疫苗部署的策略重点。在美洲，公共卫生计画和国家免疫规划通常优先考虑快速反应能力和与紧急服务的协调，而集中式政府竞标和分散式医疗保健系统的采购框架也存在差异，这影响着供应商的参与和合约签订方式。在欧洲、中东和非洲，协调监管的努力与基础设施成熟度的差异并存。有些市场拥有先进的低温运输网路和药品安全监测系统，而有些市场则需要投资于培训和最后一公里物流以扩大覆盖范围。

每家公司在生产製造、临床开发和服务导向商业模式方面的策略如何影响狂犬病疫苗的竞争优势和供应可靠性？

了解公司层面的发展趋势对于掌握人用狂犬病疫苗领域的创新管线、生产能力和商业性化进程至关重要。主要企业正投资于製程改进、细胞基材优化和品管系统，以提高产量和产品一致性。先行生产商与区域契约製造生产商之间的策略合作，有助于扩大生产规模、加速市场准入，同时也能应对多个司法管辖区的监管核准。此外，多家机构正在推动临床研究，以优化给药方案并评估不同族群的免疫抗原性，从而兼顾安全性和计画可行性。

与製造商、采购负责人和公共卫生领导人一起采用切实可行的高优先级建议，以增强供应韧性、提高专案效率并公平获得狂犬病疫苗。

产业领导者应优先致力于增强供应韧性、提高专案效率并加快人用狂犬病疫苗的公平获取。首先，投资于生产冗余和区域生产伙伴关係将有助于降低贸易相关成本衝击的影响，并提高前置作业时间的可预测性。其次，加强医护人员皮内注射的训练（皮内注射可节省剂量），并统一各辖区的临床指南，将有助于扩大疫苗接种覆盖范围，同时有效管理耗材使用和低温运输负荷。第三，销售部门应与公共卫生机构合作，推动联合采购协议和共同采购机制，以稳定需求并促进长期生产能力的投资。

我们采用严谨的多面向调查方法，结合专家访谈、监管机构审查和实际案例研究分析，为决策者提供了切实可行的见解。

本执行摘要的研究基础建构了一个多方面的证据库，该证据库结合了对关键相关人员的访谈、同行评审的科学文献、监管文件和营运案例研究。主要研究包括对临床专家、供应链经理、采购负责人和销售主管的访谈，以了解实际营运、临床偏好和合约惯例。二级资讯来源包括监管指南、疫苗生产技术专着以及已发表的关于给药策略和免疫抗原性的研究，这些资料与不同医疗保健系统的专案营运经验相结合。

总结了科学进展、专案重点和策略挑战，以加快有效进行狂犬病预防和控制活动。

本执行摘要概述了参与透过疫苗接种策略预防和控制人类狂犬病的相关人员需要考虑的关键因素。科学进步和供应链创新为扩大疫苗接种覆盖范围提供了明确的机会，但要实现这些机会，需要在生产、采购和临床实践等各个环节开展协调一致的努力。关税和贸易的考量凸显了全球供应链网路的脆弱性，以及风险意识采购和区域间生产合作的重要性。针对各个环节的分析揭示了临床方案、製剂选择和分销管道如何相互作用并影响项目的可行性和推广。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：人用狂犬疫苗市场：依疫苗类型划分

  • 暴露后预防
  • 暴露前预防

第九章：人用狂犬疫苗市场：依疫苗分类

  • 人类二倍体细胞
  • 纯化的鸡胚细胞
  • 纯化的Vero细胞

第十章：人用狂犬疫苗市场：依给药途径划分

  • 皮内注射
  • 肌肉内部

第十一章 人类狂犬病疫苗市场：以剂型划分

  • 液体
  • 冷冻干燥

第十二章 人类狂犬疫苗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：人用狂犬疫苗市场：依最终用户划分

  • 诊所
  • 医院
  • 研究机构

第十四章 人类狂犬病疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 人类狂犬病疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 人类狂犬病疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国狂犬病疫苗市场

第十八章：中国狂犬病疫苗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bavarian Nordic A/S
  • Beijing Minhai BIoTechnology Co., Ltd.
  • Bharat BIoTech International Limited
  • Bio-Med Pvt. Ltd.
  • Cadila Healthcare Ltd.
  • Changchun Institute of Biological Products Co., Ltd.
  • Chengda BIoTechnology Co., Ltd.
  • China National Pharmaceutical Group Co., Ltd.
  • GlaxoSmithKline plc
  • Hualan Biological Engineering Inc.
  • Indian Immunologicals Limited
  • Medigen BIoTechnology Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • PT Bio Farma（Persero）Tbk
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Sinovac BIoTech Ltd.
  • Valneva SE
Product Code: MRR-710B1F0AC439

The Human Rabies Vaccines Market was valued at USD 1.10 billion in 2025 and is projected to grow to USD 1.15 billion in 2026, with a CAGR of 4.76%, reaching USD 1.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.10 billion
Estimated Year [2026] USD 1.15 billion
Forecast Year [2032] USD 1.52 billion
CAGR (%) 4.76%

A strategic introduction to human rabies vaccines highlighting clinical urgency, recent technological advances, and the policy priorities that shape stakeholder decision-making

Human rabies vaccines remain a cornerstone of global public health interventions against a disease that is nearly always fatal once clinical signs appear. Advances in immunology, manufacturing platforms, and administration techniques have improved vaccine safety profiles and logistical feasibility, yet persistent gaps in access, awareness, and cold chain infrastructure create uneven protection across geographies. The clinical imperative is clear: prevention through vaccination and timely post-exposure prophylaxis is the most effective means to avert mortality and limit transmission.

Stakeholders across research, clinical practice, policy, and commercial operations must reconcile short-term programmatic needs with long-term ambitions for universal access. Recent technological innovations, including cell-culture-derived antigens and dose-sparing intradermal schedules, offer pathways to expand reach while containing costs. At the same time, regulatory harmonization and strengthened surveillance systems are essential to translate scientific advances into scalable public health outcomes. This introduction frames the subsequent analysis by underscoring where clinical urgency, scientific opportunity, and strategic action intersect to shape decisions across the vaccine lifecycle.

How scientific innovation, delivery optimization, and cross-sector partnerships are reshaping the global human rabies vaccine landscape and programmatic priorities

The landscape for human rabies vaccines is undergoing transformative shifts driven by scientific innovation, programmatic optimization, and evolving delivery ecosystems. Novel manufacturing approaches and improvements in cell substrate technologies have reduced reactogenicity and enabled more consistent antigen quality, which, coupled with enhanced regulatory frameworks, has accelerated approval pathways in several jurisdictions. Concurrently, adoption of intradermal administration and dose-sparing schedules is reshaping immunization programs by improving cost-efficiency and increasing the number of individuals who can be protected with the same supply base.

Market dynamics are also influenced by shifts in procurement strategies and public-private collaborations that aim to secure stable supply lines while incentivizing manufacturing scale-up. Integration of vaccine delivery with broader One Health initiatives and targeted awareness campaigns has strengthened the interface between animal rabies control programs and human prophylaxis efforts, creating synergistic opportunities to reduce incidence. These shifts are creating a more resilient and adaptable ecosystem, but sustainable progress depends on aligning manufacturing capacity, distribution innovations, and cross-sector policy commitments to ensure equitable access.

Assessing how 2025 US tariff changes influence supply chains, procurement strategies, and manufacturing localization decisions for human rabies vaccines

Recent tariff discussions and trade policy adjustments in the United States for 2025 have introduced new considerations for the production, procurement, and distribution of human rabies vaccines. Tariffs can affect downstream costs for imported raw materials, biologics, and finished vaccines, which in turn influence procurement strategies for public health buyers and private distributors. When tariffs increase input costs, manufacturers may adjust sourcing strategies, pursue greater localization of key production stages, or renegotiate supplier arrangements to protect margins and maintain supply reliability.

These trade measures also have implications for inventory planning and contractual risk allocation. Health systems and procurement agencies may lengthen lead times, diversify supplier bases, or increase buffer stocks to mitigate potential price volatility and delivery delays. For multinational manufacturers, tariff-driven cost pressures can accelerate onshoring investments or strategic partnerships with local contract manufacturing organizations to reduce exposure to cross-border levies. At the policy level, stakeholders may engage in advocacy to minimize trade barriers for essential biologics, emphasizing public health imperatives and the potential downstream costs of disrupted prophylaxis availability. Overall, tariff dynamics underscore the need for proactive supply chain risk management and flexible procurement frameworks to ensure continuity of access to rabies vaccines.

Segment-driven insights across vaccine types, classes, administration routes, formulations, end users, and distribution channels that shape clinical adoption and commercial strategy

Segment-specific insights reveal differentiated demand drivers, clinical considerations, and commercial pathways across vaccine types, classes, administration routes, formulations, end users, and distribution channels. Analysis by Vaccine Type shows distinct operational dynamics between post-exposure prophylaxis and pre-exposure prophylaxis: post-exposure programs prioritize rapid access, emergency logistics, and integration with wound care and immunoglobulin therapies, whereas pre-exposure programs emphasize targeted outreach to high-risk populations and occupational immunization scheduling. When considered by Vaccine Class, differences between Human Diploid Cell, Purified Chick Embryo Cell, and Purified Vero Cell vaccines have implications for tolerability, production scalability, and regulatory familiarity in various regions, shaping adoption curves and procurement preferences.

Route of Administration segmentation between intradermal and intramuscular approaches highlights trade-offs in dose efficiency, training requirements, and programmatic acceptance; intradermal strategies can enable dose-sparing but require provider proficiency and sometimes regulatory endorsement. Formulation distinctions between liquid and lyophilized presentations influence cold chain obligations, reconstitution practices, and vial-sharing strategies in clinic workflows. End User segmentation across clinics, hospitals, and research institutes underscores divergent procurement cycles and clinical protocols; clinics often serve as first responders in community settings, hospitals manage complex exposure cases and inpatient prophylaxis, and research institutes drive innovation and clinical evaluation. Distribution Channel segmentation among hospital pharmacies, online pharmacies, and retail pharmacies affects accessibility and last-mile delivery considerations, with each channel presenting unique regulatory and logistics implications. Together, these segment lenses enable nuanced program design and targeted commercial approaches that reflect clinical needs and operational realities.

Regional variations in epidemiology, regulatory frameworks, and delivery capacities that dictate differentiated strategies for vaccine deployment across major geographies

Regional dynamics create important variations in disease burden, regulatory pathways, and delivery system capabilities that inform strategic priorities for vaccine deployment. In the Americas, public health programs and national immunization schedules often prioritize rapid response capacity and integration with emergency services, while procurement frameworks vary between centralized government tenders and decentralized health systems, affecting how suppliers engage and contract. In Europe, Middle East & Africa, regulatory harmonization efforts coexist with diverse infrastructure maturity; some markets have advanced cold chain networks and pharmacovigilance systems, while others require investment in training and last-mile logistics to expand coverage.

Across the Asia-Pacific region, a combination of high-risk populations, evolving manufacturing bases, and policy focus on disease elimination drives interest in both scalable production and innovative delivery models. Regional financing mechanisms and bilateral partnerships frequently support capacity building, surveillance strengthening, and public awareness campaigns. These geographic distinctions necessitate differentiated market entry, pricing, and stakeholder engagement strategies that align with local epidemiology, regulatory expectations, and health system capabilities, enabling more effective allocation of resources and tailored program design.

How company strategies in manufacturing, clinical development, and service-oriented commercial models are shaping competitive advantage and supply reliability for rabies vaccines

Company-level dynamics are critical to understanding innovation pipelines, manufacturing capacity, and commercial reach within the human rabies vaccine space. Leading players are investing in process improvements, cell-substrate optimization, and quality control systems to enhance yield and product consistency. Strategic alliances between originator manufacturers and regional contract producers are enabling scale-up and faster market entry while managing regulatory acceptance in multiple jurisdictions. Several organizations are also advancing clinical studies to refine dosing regimens and evaluate immunogenicity across demographic groups, addressing both safety considerations and programmatic feasibility.

Competitive positioning increasingly reflects capabilities beyond the vial, encompassing training programs for intradermal administration, cold chain support initiatives, and digital tools for adverse event reporting and inventory management. In parallel, companies that can demonstrate reliability of supply, robust pharmacovigilance, and collaborative procurement approaches often secure longer-term institutional relationships. These dynamics favor organizations with integrated commercial models that combine manufacturing excellence, regulatory expertise, and proactive engagement with public health purchasers and clinical networks.

Practical and prioritized recommendations for manufacturers, procurers, and public health leaders to strengthen supply resilience, program efficiency, and equitable access to rabies vaccines

Industry leaders should prioritize actions that strengthen supply resilience, enhance programmatic efficiency, and accelerate equitable access to human rabies vaccines. First, investing in manufacturing redundancy and regional production partnerships will reduce exposure to trade-related cost shocks and improve lead-time predictability. Second, strengthening provider training for dose-sparing intradermal administration and harmonizing clinical guidelines across jurisdictions can expand reach while managing consumable utilization and cold chain load. Third, commercial teams should pursue collaborative procurement agreements with public health agencies and pooled purchasing mechanisms to stabilize demand and enable longer-term capacity investments.

Additionally, companies and public health institutions should deepen engagement with One Health initiatives to synchronize animal rabies control and human prophylaxis efforts, thereby amplifying impact. Investing in digital inventory and pharmacovigilance tools will improve responsiveness and build trust with regulators and buyers. Finally, scenario-based supply chain planning that explicitly accounts for tariff variability, raw material constraints, and geopolitical disruptions will position organizations to respond swiftly to emergent risks while sustaining program continuity and stakeholder confidence.

A rigorous, multi-source research methodology combining expert interviews, regulatory review, and operational case analysis to produce actionable insights for decision-makers

The research underpinning this executive summary combines primary stakeholder interviews, peer-reviewed scientific literature, regulatory documents, and operational case studies to create a multi-dimensional evidence base. Primary consultations included clinical experts, supply chain managers, procurement officials, and commercial leaders to capture frontline operational realities, clinical preferences, and contracting practices. Secondary sources comprised regulatory guidelines, technical monographs on vaccine production, and published studies on dosing strategies and immunogenicity, which were synthesized with programmatic experience from diverse health systems.

Analytical methods integrated qualitative thematic analysis with comparative policy review to surface operational constraints and strategic levers. Risk and sensitivity assessments were used to explore implications of trade policy shifts, manufacturing localization decisions, and administration-route adoption. Throughout the research process, data integrity checks and cross-validation against independent clinical and regulatory sources ensured that findings reflect established science and practical program considerations, enabling robust, actionable insights for decision-makers.

A concise conclusion synthesizing scientific progress, programmatic priorities, and strategic imperatives to accelerate effective rabies prevention and control efforts

This executive summary synthesizes key considerations for stakeholders engaged in the prevention and management of human rabies through vaccination strategies. Scientific advances and delivery innovations present clear opportunities to expand access, but realizing those gains requires coordinated action across manufacturing, procurement, and clinical practice. Tariff and trade considerations underscore the fragility of global supply networks and the importance of risk-aware sourcing and regional production collaboration. Segment-focused analysis highlights how clinical protocols, formulation choices, and distribution channels interact to shape programmatic feasibility and uptake.

For leaders in public health and commercial operations, the path forward involves aligning technical innovation with pragmatic program design, investing in provider training and supply resilience, and pursuing partnerships that synchronize animal and human health objectives. By adopting these integrated approaches, stakeholders can improve prophylaxis availability, enhance response capacity to exposures, and contribute to broader goals of rabies prevention and control across diverse health system contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Rabies Vaccines Market, by Vaccine Type

  • 8.1. Post Exposure Prophylaxis
  • 8.2. Pre Exposure Prophylaxis

9. Human Rabies Vaccines Market, by Vaccine Class

  • 9.1. Human Diploid Cell
  • 9.2. Purified Chick Embryo Cell
  • 9.3. Purified Vero Cell

10. Human Rabies Vaccines Market, by Route Of Administration

  • 10.1. Intradermal
  • 10.2. Intramuscular

11. Human Rabies Vaccines Market, by Formulation

  • 11.1. Liquid
  • 11.2. Lyophilized

12. Human Rabies Vaccines Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Human Rabies Vaccines Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Research Institutes

14. Human Rabies Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Rabies Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Rabies Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Human Rabies Vaccines Market

18. China Human Rabies Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bavarian Nordic A/S
  • 19.6. Beijing Minhai Biotechnology Co., Ltd.
  • 19.7. Bharat Biotech International Limited
  • 19.8. Bio-Med Pvt. Ltd.
  • 19.9. Cadila Healthcare Ltd.
  • 19.10. Changchun Institute of Biological Products Co., Ltd.
  • 19.11. Chengda Biotechnology Co., Ltd.
  • 19.12. China National Pharmaceutical Group Co., Ltd.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Hualan Biological Engineering Inc.
  • 19.15. Indian Immunologicals Limited
  • 19.16. Medigen Biotechnology Corporation
  • 19.17. Merck & Co., Inc.
  • 19.18. Novartis AG
  • 19.19. PT Bio Farma (Persero) Tbk
  • 19.20. Sanofi SA
  • 19.21. Serum Institute of India Pvt. Ltd.
  • 19.22. Shenzhen Kangtai Biological Products Co., Ltd.
  • 19.23. Sinovac Biotech Ltd.
  • 19.24. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HUMAN DIPLOID CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HUMAN DIPLOID CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HUMAN DIPLOID CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED CHICK EMBRYO CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED CHICK EMBRYO CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED CHICK EMBRYO CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED VERO CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED VERO CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED VERO CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. GCC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. G7 HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. NATO HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 151. NATO HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)